- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of p...
10XB-101 is a Novel Potential Best-in-Class Injectable Drug Being Developed for Focal Fat Reduction and Body Contouring Second Major Regional Lice...
HUTCHMED (China) Limited announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanc...
Andelyn Biosciences, Inc., a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Q...
Announcing expansion of capabilities to provide customers with a broader range of DNA synthesis solutions, allowing IDT to complement and extend ...
Johnson & Johnson announced that the European Commission (EC) has approved an indication extension for TECVAYLI®(teclistamab) in combination with...
New Curitics Point of Care Solution, Ambient Listening, AI Care Management, and mobile capabilities help reduce administrative burden, strengthen care co...
GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to redu...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces a breakthrough in RF resection technology for hip with its new FLOW FLE...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced to...
HUTCHMED (China) Limited announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO®...
-Enigma Biomedical USA (EB USA) today announced the U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection, a...
NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative t...
Prescription Drug User Fee Act target action date is February 12, 2027 If approved, tinlarebant would be the first-ever approved treatment for Stargar...
© 2026 Biopharma Boardroom. All Rights Reserved.
